絞り込み

16638

広告

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

著者 Cohen AT , Hamilton M , Mitchell SA , Phatak H , Liu X , Bird A , Tushabe D , Batson S
PLoS One.2015 ; 10(12):e0144856.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (435view , 0users)

Full Text Sources

Medical

Miscellaneous

Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) treatment and prevention. Although novel oral anti-coagulants (NOACs) have been compared with SOC in this indication, no head-to-head randomised controlled trials (RCTs) have directly compared NOACs. A systematic review and network meta-analysis (NMA) were conducted to compare the efficacy and safety of NOACs for the initial and long-term treatment of VTE.
PMID: 26716830 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード